XORTX Therapeutics Inc. (NASDAQ:XRTX) Stock Short Interest Rises 424.5%

XORTX Therapeutics Inc. (NASDAQ:XRTX) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 76,755 shares, an increase of 424.5% from the August 31st total of 14,635 shares. Based on an average trading volume of 367,812 shares, the short-interest ratio is presently 0.2 days. Currently, 4.5% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of XORTX Therapeutics in a report on Monday. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, XORTX Therapeutics has an average rating of “Sell”.

XORTX Therapeutics Trading Up 1.2%

XRTX opened at $1.72 on Friday. The stock has a 50-day moving average of $2.09 and a 200 day moving average of $2.20. XORTX Therapeutics has a 12 month low of $1.59 and a 12 month high of $7.05. The firm has a market cap of $3.13 million, a P/E ratio of -0.63 and a beta of 0.75.

XORTX Therapeutics (NASDAQ:XRTX) last posted its quarterly earnings data on Saturday, August 15th. The technology company reported ($1.05) earnings per share (EPS) for the quarter.

XORTX Therapeutics Company Profile

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapies for diseases associated with abnormal uric acid metabolism and progressive kidney injury. The company’s research is centered on reducing uric acid production and addressing the role of uric acid in inflammation and renal disease.

XORTX’s development programs include XRx-008 for autosomal dominant polycystic kidney disease, a genetic condition that causes cysts to form in the kidneys, as well as programs investigating xanthine oxidase inhibition in other kidney-related conditions.